Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Click to view more


2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NYTsbVE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIraZ5lKSzVyPUCuNVLjiIoEsfMAjVAvODFizszN NEDLTFIzPTl4MEK4Ni=>
KellyCis83 NIHBdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvlWVlMUUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> NH3neZAzPTl4MEK4Ni=>
SK-N-AS NI\ydm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP MYiyOVk3ODJ6Mh?=
SK-N-ASCis24 M17vPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP MUGyOVk3ODJ6Mh?=
U87 NWnvWWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMVUxKM7:TR?= NUPGXpk5PDhiaB?= MVPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? NYjFTZdrOjV5NUCyO|M>
HCT116 M3zkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL1VFkxNjVvMj61JO69VQ>? M4jwdVQ5yqCqwrC= MnjGTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP M1rWPVI2PzR4N{[z
HT-29 NGG1fnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;mZ|kxNjVvMj61JO69VQ>? MoXYOFjDqGkEoB?= NETkbG1KSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= NHTNOnIzPTd2Nke2Ny=>
Caco2 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTFUHQxNjVvMj61JO69VQ>? NVX2[Ih1PDkEoHlCpC=> NXnBPGhrUUN3ME23MlI3yqEEsdMgNU43QMLizszN MlHwNlU4PDZ5NkO=
COLO 205 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[wMlUuOi53IN88US=> MlWyOFjDqGkEoB?= MlP0TWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NXjBUpBYOjV5NE[3OlM>
SW480 NFHqSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvNE42NTJwNTFOwG0> MlXMOFjDqGkEoB?= MlSwTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M3;kUVI2PzR4N{[z
HEK293T M1jJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjOd3gyNTVizszN NWfVOmRiPDkEoHlCpC=> NXrJXVVmUUN3ME2yMlQzyqEEsdMgNE4xPcLizszN NIrweHozPTd2Nke2Ny=>
Hep3B  M2fCSGZ2dmO2aX;uJGF{e2G7 M3jiZ|ExKM7:TR?= MlXtOFjDqGkEoB?= Mor1doVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> M4qzSFI2PjN|NU[0
Hep3B  MmL4SpVv[3Srb36gRZN{[Xl? NIXtUIgxNjFvMUCg{txO NF7sUIozPCCq NEPhWVF{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= NUPCbYFUOjV4M{O1OlQ>
HEK293 NVTNbXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? M1PieVI2PjB|MUKy
DU145 NV\Y[4lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwMklCpOKyyqByLkC0xsDPxE1? MkH3NlU3ODNzMkK=
HCT15 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPScJU2UUN3ME2wMlgyyqEEsdMgNE4xOcLizszN M1HYfVI2PjB|MUKy
T47D M3zjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXBWI5KSzVyPUOuNVjDqMLzwrCwMlEyyqEQvF2= Mm\ENlU3ODNzMkK=
SMMC-7721 MVjGeY5kfGmxbjDBd5NigQ>? M1qwPFQxKM7:TR?= NVPOZoIyPDhiaB?= NGPD[WpFVVOR M3u5dYlv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v NVPO[VhzOjV3NESzOlE>
MDA-MB-231 M2Gwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK3NuKhcA>? NHThZphKSzVyPUKxMlLDqMLzwrC0MlLDqM7:TR?= NVGyPYh6OjV2OE[yNVk>
Jurkat NYrnTHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfSU5VPPzMEoHi= NU\qTJFYUUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= NYPMVG57OjV2OE[yNVk>
HeLa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjFXm1rPzMEoHi= MkHxTWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? NX;BS4RFOjV2OE[yNVk>
MCF7  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO4OU0yODBizszN NEjO[3E4KGR? Ml6zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXrzPJdHOjV2N{K2NVk>
K562 NUHjc2tIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrLdHdYPzMEoHi= NVrCcnVRUUN3ME2wMlI6yqEQvF2= NETDVIczPTJ6Mk[1Ny=>
K/VP.5 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPMdpk4OsLiaB?= MmiyTWM2OD12LkpCpO69VQ>? MYWyOVI5OjZ3Mx?=
SH-EP  MlX4SpVv[3Srb36gRZN{[Xl? NVrPTGZCOjEEoN88[{9udA>? NEfHemMzPMLiaB?= Mmf6bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= NYDUcGhxOjV{NkG5PFE>
CAL27 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;YN|AzPMLiaB?= M4fKcWlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= M1LkVFI2OjJyN{K5
FaDu MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;kXlI1yqCq NEHOTlBKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN NF;E[WgzPTJ{MEeyPS=>
SCC25 NYnLVG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC0POKhcA>? NI\vOHVKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN NXL1OWxHOjV{MkC3Nlk>
CAL27 NFr4ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXXOFjDqGh? NF;MNW5KSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN NH3iSmkzPTJ{MEeyPS=>
FaDu MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO0POKhcA>? NXLrc2t1UUN3ME22MlQ{yqEEsdMgNU4yO8LizszN NVXoTYFZOjV{MkC3Nlk>
SCC25 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPT|czyqCq M2jvNWlEPTB;OD60NeKhyrIEoEGuNVHDqM7:TR?= M1vZW|I2OjJyN{K5
CAL27 M3jSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\oNlczyqCq MmrSTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP M{L1OVI2OjJyN{K5
FaDu MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH5dW9tPzMEoHi= M4XENGlEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= MoryNlUzOjB5Mkm=
MCF-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfPN|B2PDkEoHlCpC=> NWLEbJlsTE2VTx?= M3nheWlEPTB;Nz6yxsDDucLiMD64xsDPxE1? NHezenczPTJzNkO3PC=>
T-47D M4PZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPDRoZlPDkEoHlCpC=> MYTEUXNQ M4DhWWlEPTB;Nz63xsDDucLiMD63xsDPxE1? MnnKNlUzOTZ|N{i=
MDA-MB-231 NEGzdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO0POKhcMLi MVrEUXNQ MoPtTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? M1rxW|I2OjF4M{e4
DU145 NGHNU3hCeG:ydH;zbZMhSXO|YYm= MXuxNE0yODBizszN NU\hXHNzQCCq Mm\zSG1UVw>? M1S5Xolv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NUfie2NnOjVzNEm2PFE>
DU145 stem-like NEKyUVJCeG:ydH;zbZMhSXO|YYm= MkfMNVAuOTByIN88US=> NYXCOpc1QCCq M{\KVmROW09? MlPGbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1P0NlI2OTR7Nkix
DU145 stem-like NWPOSnBrTnWwY4Tpc44hSXO|YYm= NXi1UXNiOTBvMUCwJO69VQ>? MUmyJIg> M1PyUGROW09? NFfr[m5qdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUmyOVE1QTZ6MR?=
UW228-3 M2jNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK3NE4xOS1|MECg{txO NVribVFwPDhiaB?= M4jvWGROW09? M{CxNGlEPTB;MD65PeKh|ryP NHLibVAzPTFzOUG4OS=>
NSCs MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMlAyNTNyMDFOwG0> NULBWoM1PDhiaB?= MoDJSG1UVw>? MlizTWM2OD1yLkOtN:Kh|ryP M2n2e|I2OTF7MUi1
MKL-1  NFjEfHlHfW6ldHnvckBCe3OjeR?= MVuxNE0yODByIH7N M2Cwb|Qh\A>? NWnIR29ocW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= NHfBTnQzPTFzNke1OC=>
MCF7 EV NXruW|ZyTnWwY4Tpc44hSXO|YYm= MVmxNE0yODBizszN NGHmWGQz6oDLaB?= M2jtXYlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ NFfZRVQzPTB6OEKwNy=>
MCF 7BMI1 M1PZTGZ2dmO2aX;uJGF{e2G7 MUKxNE0yODBizszN MnzWNwKBkWh? NFfoWGNqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NILC[4EzPTB6OEKwNy=>
MCF7 EV MlzISpVv[3Srb36gRZN{[Xl? NGLTe4IyOC1zMECg{txO NFqwWYoz6oDLaB?= MkDaSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u Mlr1NlUxQDh{MEO=
MCF7 BMI1 M36ybGZ2dmO2aX;uJGF{e2G7 M4XsdlExNTFyMDFOwG0> MWWy5qCKcA>? M4XwVmVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> MmXJNlUxQDh{MEO=
HT1080 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm0fHEyNTFyMDFOwG0> MYe0M|I1NzR6IHi= M3u1fWROW00EoB?= NX74RZV1cW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u MnnpNlUxPzhyNkS=
HT1080 MVvGeY5kfGmxbjDBd5NigQ>? NYjaOWhUOC5yMECxMVExOCEQvF2= MXyxMVI1KGh? M3zQTmROW00EoB?= NXO5fFZ3cW6mdXPld{BxNXB3Mzjz[ZIyPSliaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MVmyOVA4QDB4NB?=
HT1080 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33RelAvODByMT2xNFAh|ryP MoG0NlQhcA>? NITCZpRFVVORwrC= Mlj0Z4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= MVSyOVA4QDB4NB?=
HD-MY-Z MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG4NlQwPDhxN{KgbC=> NUfTfWdqUUN3MP-8olExOCEQvF2= M3mySVI2ODR6MkO2
DOHH-2 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGyOEBp M1T6VmlEPTExvK6xNFAh|ryP MUCyOVA1QDJ|Nh?=
DOHH-2 M17YTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml72OFghcA>? NG[2OGVKSzVyPUG5MlnDqM7:TR?= NHrMZZozPTB2OEKzOi=>
DOHH-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofpO|IhcA>? NYHQR4JGUUN3ME21xsDPxE1? NFXaWFkzPTB2OEKzOi=>
REH NFf4SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu0PEBp NGe3S4dKSzVyPUCuNFE1yqEQvF2= M4XhOVI2ODR6MkO2
REH Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j1ZVczKGh? M2HnWGlEPTB;MD6wNVXDqM7:TR?= MmDQNlUxPDh{M{[=
HH M1jS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjJToMzPCCq Ml;YTWM2OD1zMESuO:Kh|ryP M1\mT|I2ODR6MkO2
HH NHzm[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ielY1QCCq M1\sdWlEPTB;NEiuOuKh|ryP MkX4NlUxPDh{M{[=
HH MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW2eFhyPzJiaB?= NWnMd2VWUUN3ME2xOE44yqEQvF2= M1u4eVI2ODR6MkO2
HuT-78 NEj2XIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvKNlQhcA>? NVHZ[45wUUN3ME25MlPDqM7:TR?= NWPU[2wyOjVyNEiyN|Y>
HuT-78 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL3ZmxJPDhiaB?= MVnJR|UxRTRwM9Mg{txO MV6yOVA1QDJ|Nh?=
HuT-78 M4HDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHjT3g4OiCq NFG1ZYdKSzVyPUSuNuKh|ryP Mn\hNlUxPDh{M{[=
OPM-2 NI\rN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq5NlQhcA>? NFy2dGxKSzVyPUK0MlHDqM7:TR?= M2TITVI2ODR6MkO2
OPM-2 M1;SS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[0PEBp NUPmPHplUUN3ME20xsDPxE1? MmnTNlUxPDh{M{[=
OPM-2 NGnGZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PwPVczKGh? MW\JR|UxRTFwM9Mg{txO NXvyUnF6OjVyNEiyN|Y>
RPMI-8226 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\ETGFYOjRiaB?= MUXJR|UxRTFyNj62xsDPxE1? NFf0emgzPTB2OEKzOi=>
RPMI-8226 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX20PEBp M4rHXWlEPTB;OUGuNeKh|ryP NGDud5YzPTB2OEKzOi=>
RPMI-8226 NHjEWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[3NkBp MVfJR|UxRTF2LkpCpO69VQ>? M37RblI2ODR6MkO2
U-266 NED3TVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXqNlQhcA>? NV63PIVnUUN3ME24Ok4zyqEQvF2= MlL4NlUxPDh{M{[=
U-266 M{SzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfIZ|E1QCCq Mn\3TWM2OD14OD60xsDPxE1? M1y3UVI2ODR6MkO2
Kelly NGfRfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7vNE0yOCEQvF2= MV[3NuKhcA>? NG\Hd|VKSzVyPUGuOVE5yqEQvF2= M4\Pe|I2ODB6OUCw
SH-SY5Y  MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fCO|AuOTBizszN NWT6[ZB5PzMEoHi= NXfpbIRVUUN3ME2wMlc2PMLizszNxsA> NGm3S2ozPTByOEmwNC=>
SK-N-AS NIH0cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMVExKM7:TR?= NGnsZnM4OsLiaB?= NU[zdpdFUUN3ME2xMlcyOsLizszNxsA> MVKyOVAxQDlyMB?=
SK-N-DZ NFvwU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknCNE0yOCEQvF2= MoLzO|LDqGh? NGnG[WRKSzVyPUWuOFg2yqEQvF2= NUnUboZlOjVyMEi5NFA>
HepG2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;3OFjDqGh? M{PFTmROW00EoB?= MmrBTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= M4\aPVI1QTl4MUO2
A549 NIOwRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS0POKhcA>? MVHEUXNQyqB? NW\sOHlqUUN3ME2yOFEvQcLiwsJCpFMyNjJ|wrFOwG0> M{DSbVI1QTl4MUO2
MCF7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu0POKhcA>? M2G5emROW00EoB?= M4PSeWlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN NFvZOogzPDl7NkGzOi=>
HL-60  MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG5O|LDqGh? MUnJR|UxRTBwMUNihKXPxE1? NWDseXNsOjR7OUOwNVQ>
HL-60[R] MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLsXm9CPzMEoHi= MW\JR|UxRTNwMUNihKXPxE1? NVrwXFE6OjR7OUOwNVQ>
HeLa Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3HTVUxRTBwNkSgxtEhOC52IN88US=> MUiyOFk2Ozh{MR?=
MO59K  M4X5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\YR|ch\A>? NEOxcJFKSzVyPUCuNVfjiIYQvF2= M4fwNlI1QTV|NU[x
MO59J MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDJTXc4KGR? MXXJR|UxRTBwMfMAie69VQ>? NUfkO|luOjR7NUO1OlE>
ME 180 M4TnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TFO|Q5yqCqwrC= NYf2SXFKUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= NEHNeWEzPDl3M{CyOy=>
MCF-7 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TJblQ5yqCqwrC= MkTyTWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? MlrMNlQ6PTNyMke=
HeLa M1;ieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnjcWE1QMLiaNMg MnXHTWM2OD12LkexJOKyKDFwNPMAie69VQ>? M4Tre|I1QTV|MEK3
MDA-MB-453 NVLRe3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\1OFjDqGkEoB?= NGXte4tKSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= NITs[W0zPDl3M{CyOy=>
MDA-MB-231 M3vM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPyO|hCPDkEoHlCpC=> Ml3STWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP NIfwc|UzPDl3M{CyOy=>
PC-3 M1L2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX2b|E1QMLiaNMg MV3JR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? MljwNlQ6PTNyMke=
HT-29 M33HXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHzWYc1QMLiaNMg MVvJR|UxRTJzLkS1JOKyKDNwOEhihKXPxE1? MWSyOFk2OzB{Nx?=
BGC-823 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe0POKhcMLi NWDQNlJuUUN3ME20N{44PCEEsTC1MlE{6oDHzszN MkG0NlQ4QTN6N{e=
A549 NWjUU|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f3PFQ5yqCqwrC= NGL6RXZKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN M3T6W|I1Pzl|OEe3
HK-2 M1PZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7WWlM1QMLiaNMg MlTqTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? NYrzTIFJOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]


Kinase Assay
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56


CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02819999 Not yet recruiting Small Cell Lung Cancer Stemcentrx October 2016 Phase 1
NCT01775475 Not yet recruiting AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation September 2016 Phase 2
NCT02815592 Not yet recruiting Small Cell Lung Cancer Bristol-Myers Squibb September 2016 Phase 1|Phase 2
NCT02483000 Not yet recruiting Adult Burkitt Lymphoma|Adult Diffuse Large B-Cell Lymphoma|CD20-Positive Neoplastic Cells Present|Indolent Adult Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory Mature B-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) September 2016 Phase 1
NCT02538926 Not yet recruiting B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma University of Washington|National Cancer Institute (NCI) August 2016 Phase 2
NCT02722369 Not yet recruiting Small Cell Lung Cancer University College, London August 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. ; 2.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID